Literature DB >> 17605116

[Focus on tumor immunology of transitional cell carcinoma].

P J Olbert1, A J Schrader, A Hegele, R Hofmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17605116     DOI： 10.1007/s00120-007-1464-9

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  7 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

Review 2.  Therapeutics targeting the innate immune system.

Authors:  Richard J Ulevitch
Journal:  Nat Rev Immunol       Date:  2004-07       Impact factor: 53.106

3.  Immunostimulatory CpG oligonucleotides reduce tumor burden after intravesical administration in an orthotopic murine bladder cancer model.

Authors:  A Hegele; A Dalpke; K Heeg; P Barth; Z Varga; R Hofmann; P Olbert
Journal:  Tumour Biol       Date:  2005-08-09

4.  Antineoplastic effect of immunostimulatory DNA (CpG-ODN) in a murine C57-BL6/MB-49 transitional cell carcinoma model.

Authors:  Axel Hegele; Alexander Dalpke; Peter Barth; Zoltan Varga; Klaus Heeg; Rainer Hofmann; Peter Olbert
Journal:  Anticancer Res       Date:  2004 Jul-Aug       Impact factor: 2.480

5.  Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response.

Authors:  Elizabeth C De Boer; Sietske J Rooijakkers; Denis H Schamhart; Karl-Heinz Kurth
Journal:  J Urol       Date:  2003-11       Impact factor: 7.450

6.  Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.

Authors:  Richard J Sylvester; Adrian P M van der MEIJDEN; Donald L Lamm
Journal:  J Urol       Date:  2002-11       Impact factor: 7.450

7.  Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity.

Authors:  T Tokunaga; H Yamamoto; S Shimada; H Abe; T Fukuda; Y Fujisawa; Y Furutani; O Yano; T Kataoka; T Sudo
Journal:  J Natl Cancer Inst       Date:  1984-04       Impact factor: 13.506
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.